Senior or Exec Director of Clinical Pharmacology and Pharmacometrics Leader

US (Remote)
Role Details
Position
Senior or Exec Director of Clinical Pharmacology and Pharmacometrics Leader
Function
Clinical
Location
US (Remote)
Reports To

About the Job

Key Responsibilities

CPP Strategy & Model-Informed Drug Development (MIDD)

  • Strategy & MIDD Plans: Develop global clinical pharmacology and MIDD plans integrating nonclinical/clinical PK/PD, exposure-response, biomarkers, efficacy, safety, and immunogenicity.
  • Quantitative Recommendations: Provide data-driven guidance on FIH starting doses, escalation schemes, dosing frequency, formulations, food-effect studies, and special populations.
  • Modeling & Simulation: Direct population PK, PK/PD, exposure-response, PBPK, translational modeling, and clinical trial simulations to guide portfolio decisions.

Pre-clinical Development & Transition to Clinic

  • Candidate-to-Clinic Translation: Translate nonclinical pharmacology, DMPK, toxicology, bioanalytical, and biomarker data into human PK projections, therapeutic exposure targets, and safety margins.
  • Trial Design & Sampling: Partner with CMC, Formulation, and Clinical Ops to establish viable PK/PD/biomarker sampling plans, formulation comparability, and IND/CTA-enabling strategy.

Clinical Development, Dose Optimization & PoC

  • Dose Optimization: Integrate emerging PK/PD, safety, efficacy, and immunogenicity data to refine dosing for biologics (TMDD, body-size effects, subcutaneous vs. IV) and oral agents (absorption, food effect, DDI, organ impairment).
  • Late-Stage Alignment: Establish a clear quantitative pathway from PoC to registration, including dose justification, special population labeling, and post-approval commitments.

Operations, Risk Management & Vendor Governance

  • Execution & Oversight: Own integrated CPP plans, milestones, and budgets; select and govern external pharmacometrics, bioanalytical, and modeling vendors for quality and reproducibility.
  • Risk Mitigation: Proactively identify quantitative and translational risks, balancing development speed with scientific rigor, safety, and regulatory acceptability.

Stakeholder Communication & BD Support

  • Spokesperson: Serve as the primary CPP internal expert and external representative to health authorities (FDA/EMA/NMPA), KOLs, and governance boards.
  • Business Development: Support partnering, licensing, and due diligence activities by evaluating translational models, human PK projections, and dose feasibility.

Capabilities, Quality & Compliance

  • Capability Building: Build a scalable CPP function using internal experts, vendors, and consultants; define reusable quantitative workflows, model documentation, and data standards.
  • Regulatory Compliance: Ensure models, code, data sets, and reports comply with GCP/GLP, data integrity standards, and inspection readiness.

Qualifications, Education & Experience

Essential

  • Education: PhD, PharmD, MD, or equivalent in clinical pharmacology, pharmacometrics, pharmaceutical sciences, or quantitative discipline.
  • Experience: 5–7+ years of biotech/pharma CPP or MIDD leadership experience spanning candidate selection through FIH, dose optimization, PoC, and later-stage development.
  • Quantitative Mastery: Deep hands-on expertise in population PK, PK/PD, exposure-response modeling, clinical trial simulation, and reproducible programming workflows.
  • Regulatory Depth: Proven record authoring CPP submission sections and defending dose justification strategies before major health authorities (FDA, EMA, NMPA).
  • Cross-Functional & Vendor Oversight: Demonstrated track record integrating cross-functional data (CMC, Safety, Biomarkers) and governing external modeling/bioanalytical vendors.

Leadership Profile

  • A scientific leader who moves seamlessly between complex quantitative model outputs and high-level portfolio strategy. Decisive, collaborative, and comfortable with ambiguity, this individual influences cross-functional teams without hierarchical authority, establishing traceable and rigorous quantitative rationale for key drug development choices.

Preferred Qualifications

  • Experience in immunology, inflammation, dermatology, rheumatology, or gastroenterology.
  • Background supporting both biologics (antibodies, multispecifics, TMDD, immunogenicity) and oral therapeutic modalities (DDI, absorption, food effect).
  • Exposure to advanced quantitative tools (PBPK, QSP, disease-progression modeling, model-based meta-analysis).
  • Multi-regional development experience across the US, China, and Europe.

Skills & Competencies

Additional Information

The Company

Ailux is an innovative biotechnology company harnessing AI to accelerate breakthrough biologic therapies in difficult immune-mediated diseases and improve the lives of patients with significant unmet medical need.

Built on intelligent design and guided by people who care about transforming healthcare, our technology is redefining what is possible in biologics development, from how we select targets to how we engineer the molecules.Ailux’s vision is to light the path to new cures and fundamentally change our approach to science and drug development to redefine current treatment paradigms.

We look to continue unlocking the potential of disease biology, integrate AI-enabled biologics development, and deliver effective clinical execution.Backed by an experienced leadership team, leading scientific advisors, a highly multidisciplinary organization, and strategic partnerships in biopharma, Ailux is approaching a key inflection point as its first wave of therapeutic programs advance toward clinical development.

This is an opportunity to play a vital role in leading programs from pre-clinical development into the clinic and through clinical proof-of-concept, shaping the pipeline and development culture of a rapidly growing biotechnology company.

Ideal Candidate Profile